Clinical-stage biopharmaceutical company developing fully human IgG immunotherapies for autoimmune diseases, led by SAB-142 for Type 1 Diabetes.
SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing multi-specific, high-potency, fully human immunoglobulin G (hIgG) immunotherapies aimed at the root causes of autoimmune diseases. Its lead programme, SAB-142, is a potentially disease-modifying therapy for Type 1 Diabetes, designed to delay onset and progression by addressing the over-reactive immune response that attacks insulin-producing beta cells.
The company's work rests on two proprietary platforms. DiversitAb™ is used to develop multi-specific, high-potency, fully human IgG immunotherapies. TcBovine™ comprises genetically engineered transgenic cattle that, when vaccinated against target diseases, produce large quantities of natural human polyclonal antibodies. Together, these technologies underpin a pipeline spanning immunotherapy, immunology and autoimmune disease therapeutics.
SAB Biotherapeutics maintains its corporate headquarters in Miami Beach, FL and a research and development campus in Sioux Falls, SD. Its technical work spans transgenic animal biotechnology, fully human polyclonal antibodies and biopharmaceutical drug development. The company describes a mission-driven, collaborative environment staffed by scientists and professionals focused on root-cause treatment rather than symptom management.
